Structure-based design, synthesis, and evaluation of 4,5,6,7-tetrahydro-1 H -pyrazolo[4,3-c]pyridine derivatives as novel c-Met inhibitors

Bottaro, 1991, Identification of the hepatocyte growth factor receptor as the c-met porto-oncogene product, Science, 251, 802, 10.1126/science.1846706

Giordano, 1989, Tyrosine kinase receptor indistinguishable from the c-met protein, Nature, 339, 155, 10.1038/339155a0

Dean, 1985, The human Met oncogene is related to the tyrosine kinase oncogenes, Nature, 318, 385, 10.1038/318385a0

Gherardi, 2012, Targeting MET in cancer: rationale and progress, Nat. Rev. Cancer, 12, 89, 10.1038/nrc3205

Matsumoto, 2003, NK4 (HGF-antagonist/angiogenesis inhibitor) in cancer biology and therapeutics, Cancer Sci., 94, 321, 10.1111/j.1349-7006.2003.tb01440.x

Trusolino, 2002, Scatter-factor and semaphorin receptors: cell signalling for invasive growth, Nat. Rev. Cancer, 2, 289, 10.1038/nrc779

Cui, 2013, Targeting receptor tyrosine kinase MET in cancer: small molecule inhibitors and clinical progress, J. Med. Chem., 57, 4427, 10.1021/jm401427c

Cui, 2011, Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK), J. Med. Chem., 54, 6342, 10.1021/jm2007613

Zou, 2007, An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms, Cancer Res., 67, 4408, 10.1158/0008-5472.CAN-06-4443

Peters, 2012, MET: a promising anticancer therapeutic target, Nat. Rev. Clin. Oncol., 9, 314, 10.1038/nrclinonc.2012.71

Liu, 2011, A novel kinase inhibitor, INCB28060, blocks c-MET-dependent signaling, neoplastic activities, and cross-talk with EGFR and HER3, Clin. Cancer Res., 17, 7127, 10.1158/1078-0432.CCR-11-1157

Boezio, 2016, J. Med. Chem., 59, 2328, 10.1021/acs.jmedchem.5b01716

Hughes, 2016, In vitro and in vivo activity of AMG 337, a potent and selective MET kinase inhibitor, in MET-dependent cancer models, Mol. Cancer Ther., 15, 1568, 10.1158/1535-7163.MCT-15-0871

Elisei, 2013, Cabozantinib in progressive medullary thyroid cancer, J. Clin. Oncol., 31, 3639, 10.1200/JCO.2012.48.4659

Yakes, 2011, Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth, Mol. Cancer. Ther., 10, 2298, 10.1158/1535-7163.MCT-11-0264

Qian, 2009, Inhibition of tumor cell growth, invasion, and metastasis by EXEL-2880 (XL880, GSK1363089), a novel inhibitor of HGF and VEGF receptor tyrosine kinases, Cancer Res., 69.20, 8009, 10.1158/0008-5472.CAN-08-4889

Munshi, 2010, ARQ 197, a novel and selective inhibitor of the human c-met receptor tyrosine kinase with antitumor activity, Mol. Cancer Ther., 9.6, 1544, 10.1158/1535-7163.MCT-09-1173

Gustin, 2005, Discovery and SAR studies of a novel series of noncovalent cathepsin S inhibitors, Bioorg. Med. Chem. Lett., 15, 1687, 10.1016/j.bmcl.2005.01.045

Samala, 2013, Development of 3-phenyl-4,5,6,7-tetrahydro-1H-pyrazolo[4,3-c]pyridine derivatives as novel Mycobacterium tuberculosis pantothenate synthetase inhibitors, Eur. J. Med. Chem., 69, 356, 10.1016/j.ejmech.2013.08.036

Hu, 2015, Preparation of tetrahydro-pyrazolo[4,3-c]pyridines as c-Met kinase inhibitor for treating cancer, Faming Zhuanli Shenqing

Winters, 1985, Synthesis, in vitro [3H] prazosin displacement, and in vivo activity of 3-aryl-4,5,6,7-tetrahydropyrazolo [4,3-c] pyridines, a new class of antihypertensive agents, J. Med. Chem., 28, 934, 10.1021/jm00145a015

Wang, 2011, Synthesis and c-met kinase inhibition of 3,5-disubstituted and 3,5,7-trisubstituted quinolines: identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a novel anticancer agent, J. Med. Chem., 54, 2127, 10.1021/jm101340q

Liu, 2016, Design, synthesis and structure-activity relationships of novel 4-phenoxyquinoline derivatives containing 1,2,4-triazolone moiety as cMet kinase inhibitors, Eur. J. Med. Chem., 123, 431, 10.1016/j.ejmech.2016.07.059

Liu, 2008, Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-Hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy) pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2, 3-dihydro-1 H-pyrazole-4-carboxamide (AMG 458), J. Med. Chem., 51, 3688, 10.1021/jm800401t

Farfan, 2004, Multiplexing homogeneous cell-based assays, Cell Notes, 10, 2

Riss, 2005, Selecting cell-based assays for drug discovery screening, Cell Notes, 13, 16

Hata, 2016, Tumor cells can follow distinct evolutionary paths to become resistant to epidermal growth factor receptor inhibition, Nat. Med., 22, 262, 10.1038/nm.4040

Ma, 2015, Design and optimization of a series of 1-sulfonylpyrazolo [4, 3-b] pyridines as selective c-met inhibitors, J. Med. Chem., 58, 2513, 10.1021/jm502018y

Schrodinger, 2011

CellTiter-Glo® Luminescent Cell Viability Assay Technical Bulletin. http://cn.promega.com (Accessed 16 May 2010).